Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort
Eur Arch Psychiatry Clin Neurosci. 2018-05-28; 269(8): 985-992
DOI: 10.1007/s00406-018-0908-0
Read on PubMed
1. Eur Arch Psychiatry Clin Neurosci. 2019 Dec;269(8):985-992. doi:
10.1007/s00406-018-0908-0. Epub 2018 May 28.
Chronic low-grade peripheral inflammation is associated with ultra resistant
schizophrenia. Results from the FACE-SZ cohort.
Fond G(1)(2), Godin O(3)(4)(5), Boyer L(3)(6), Berna F(3)(7), Andrianarisoa
M(3)(4)(5), Coulon N(3)(4)(5), Brunel L(3)(4)(5), Bulzacka E(3)(4)(5),
Aouizerate B(3)(8)(9), Capdevielle D(3)(10), Chereau I(3)(11), D’Amato T(3)(12),
Dubertret C(3)(13), Dubreucq J(3)(14), Faget C(3)(15), Leignier S(3)(14), Lançon
C(3)(15), Mallet J(3)(13), Misdrahi D(3)(8)(16), Passerieux C(3)(17), Rey
R(3)(12), Schandrin A(3)(10), Urbach M(3)(17), Vidailhet P(7), Llorca PM(3)(11),
Schürhoff F(3)(4)(5), Leboyer M(3)(4)(5); FACE-SZ (FondaMental Academic Centers
of Expertise for Schizophrenia) Group.
Collaborators: Andrianarisoa M, Aouizerate B, Bazin N, Berna F, Blanc O, Brunel
L, Bulzacka E, Capdevielle D, Chereau-Boudet I, Chesnoy-Servanin G, Danion JM,
D’Amato T, Deloge A, Delorme C, Denizot H, Dorey JM, Dubertret C, Dubreucq J,
Faget C, Fluttaz C, Fond G, Fonteneau S, Gabayet F, Giraud-Baro E, Hardy-Bayle
MC, Lacelle D, Lançon C, Laouamri H, Leboyer M, Le Gloahec T, Le Strat Y, Llorca
PM, Mallet J, Metairie E, Misdrahi D, Offerlin-Meyer I, Passerieux C, Peri P,
Pires S, Portalier C, Ramet L, Rey R, Roman C, Sebilleau M, Schandrin A,
Schürhoff F, Tessier A, Tronche AM, Urbach M, Vaillant F, Vehier A, Vidailhet P,
Vilà E, Yazbek H, Zinetti-Bertschy A.
Author information:
(1)Fondation FondaMental, Créteil, France. .
(2)Faculté de Médecine – Secteur Timone, Aix-Marseille Univ, EA 3279: CEReSS –
Centre d’Etude et de Recherche sur les Services de Santé et la Qualité de vie,
27 Boulevard Jean Moulin, 13005, Marseille, France. .
(3)Fondation FondaMental, Créteil, France.
(4)INSERM U955, équipe de psychiatrie translationnelle, Créteil, France.
(5)Université Paris-Est Créteil, DHU Pe-PSY, Pôle de Psychiatrie des Hôpitaux
Universitaires H Mondor, Créteil, France.
(6)Faculté de Médecine – Secteur Timone, Aix-Marseille Univ, EA 3279: CEReSS –
Centre d’Etude et de Recherche sur les Services de Santé et la Qualité de vie,
27 Boulevard Jean Moulin, 13005, Marseille, France.
(7)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg,
France.
(8)Centre Hospitalier Charles Perrens, Université de Bordeaux, 33076, Bordeaux,
France.
(9)INRA, NutriNeuro, University of Bordeaux, U1286, 33076, Bordeaux, France.
(10)Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU
Montpellier, Université Montpellier 1, Inserm 1061, Montpellier, France.
(11)CMP B, CHU, EA 7280 Faculté de Médecine, Université d’Auvergne, BP 69,
63003, Clermont-Ferrand Cedex 1, France.
(12)INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon,
Université Claude Bernard Lyon 1, Equipe PSYR2, Centre Hospitalier Le Vinatier,
Pole Est, 95 bd Pinel, BP 30039, 69678, Bron Cedex, France.
(13)AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, Inserm
U894, Sorbonne Paris Cité, Faculté de médecine, Université Paris Diderot, Paris,
France.
(14)Centre Référent de Réhabilitation Psychosociale, CH Alpes Isère, Grenoble,
France.
(15)Assistance Publique des Hôpitaux de Marseille (AP-HM), Pôle Universitaire de
Psychiatrie, Marseille, France.
(16)CNRS UMR 5287-INCIA, Université de Bordeaux, Bordeaux, France.
(17)Service de psychiatrie d’adulte, Centre Hospitalier de Versailles, UFR des
Sciences de la Santé Simone Veil, Université Versailles Saint-Quentin en
Yvelines, Versailles, France.
A high rate of patients with schizophrenia (SZ) does not sufficiently respond to
antipsychotic medication, which is associated with relapses and poor outcomes.
Chronic peripheral inflammation has been repeatedly associated with
schizophrenia risk and particularly to poor responders to treatment as usual
with cognitive impairment in SZ subjects. The objective of present study was to
confirm if ultra resistance to treatment in schizophrenia (UTRS) was associated
to chronic peripheral inflammation in a non-selected sample of
community-dwelling outpatients with schizophrenia. Participants were
consecutively included in the network of the FondaMental Expert Centers for
Schizophrenia and received a thorough clinical assessment, including recording
of current treatment. Current psychotic symptomatology was evaluated by the
Positive and Negative Syndrome scale for Schizophrenia (PANSS). UTRS was defined
by current clozapine treatment + PANSS total score ≥ 70. Functioning was
evaluated by the Global Assessment of Functioning scale. High sensitivity CRP
(hs-CRP) was measured for each participant as a proxy to define peripheral
low-grade inflammation. 609 stabilized community-dwelling SZ subjects (mean
age = 32.5 years, 73.6% male gender) have been included. 60 (9.9%) patients were
classified in the UTRS group. In multivariate analyses, UTRS has been associated
independently with chronic peripheral inflammation (OR = 2.6 [1.2-5.7],
p = 0.01), illness duration (0R = 1.1 [1.0-1.2], p = 0.02) and impaired
functioning (OR = 0.9 [0.9-0.9], p = 0.0002) after adjustment for age, sex,
current daily tobacco smoking, metabolic syndrome and antidepressant
consumption. Peripheral low-grade inflammation is associated with UTRS. Future
studies should explore if anti-inflammatory strategies are effective in UTRS
with chronic low-grade peripheral inflammation.
DOI: 10.1007/s00406-018-0908-0
PMID: 29808267 [Indexed for MEDLINE]